Absci (ABSI) Common Equity (2020 - 2026)
Absci (ABSI) posted Common Equity of $172.0 million for Q1 2026, down 9.23% sequentially from $189.4 million in Q4 2025, and down 13.49% YoY from $198.8 million in Q1 2025.
Analysis
Absci (ABSI) Common Equity (2020 - 2026) Analysis & Trends
Absci has reported Common Equity for 7 years, with the latest figure at $172.0 million in Q1 2026.
- Quarterly Common Equity fell 13.49% year-over-year to $172.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.0 million (down 13.49% YoY) and the FY2025 annual result came in at $189.4 million, up 5.76% from the prior year.
- Common Equity slipped to $172.0 million in Q1 2026 per ABSI's latest filing, from $189.4 million in the prior quarter.
- Over five years, Common Equity peaked at $340.5 million in Q1 2022 and troughed at $172.0 million in Q1 2026.
- A 5-year average of $226.6 million and a median of $210.3 million in 2025 frame the typical range for Common Equity.
- The sharpest annual moves came in 2022 and 2023: Common Equity jumped 445.67% in 2022, then sank 35.8% in 2023.
- Over 5 years, Common Equity stood at $274.4 million in 2022, then tumbled by 35.8% to $176.2 million in 2023, then grew by 1.68% to $179.1 million in 2024, then increased by 5.76% to $189.4 million in 2025, then declined by 9.23% to $172.0 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $172.0 million, $189.4 million, and $210.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 63.55 Bn | 58.37 Bn | 1.37 Bn | 8.42 Bn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 6.76 Bn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | 2.61 Bn |
| 6 | BeOne Medicines | 39.98 Bn | 34.89 Bn | 1.53 Bn | 5.17 Bn |
| 7 | Alnylam Pharmaceuticals | 35.32 Bn | 32.01 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 28.42 Bn | 27.59 Bn | - | 9.79 Bn |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Absci | 1.40 Bn | 1.19 Bn | - | 246.13 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 246.13 Mn |
| Mar 31, 2026 | 171.97 Mn |
| Dec 31, 2025 | 189.45 Mn |
| Sep 30, 2025 | 210.34 Mn |
| Jun 30, 2025 | 173.37 Mn |
| Mar 31, 2025 | 198.80 Mn |
| Dec 31, 2024 | 179.13 Mn |
| Sep 30, 2024 | 201.34 Mn |
| Jun 30, 2024 | 221.49 Mn |
| Mar 31, 2024 | 240.11 Mn |
| Dec 31, 2023 | 176.18 Mn |
| Sep 30, 2023 | 196.42 Mn |
| Jun 30, 2023 | 215.40 Mn |
| Mar 31, 2023 | 253.97 Mn |
| Dec 31, 2022 | 274.41 Mn |
| Sep 30, 2022 | 292.94 Mn |
| Jun 30, 2022 | 316.19 Mn |
| Mar 31, 2022 | 340.50 Mn |
| Dec 31, 2021 | 366.11 Mn |
| Sep 30, 2021 | 388.01 Mn |